TELUS Health Annual Conference 2020
Specialty drugs continued to drive growth in possible spending by private drug plans, and the latest claims data indicate that utilization, rather than cost per claim, was a leading factor behind that trend. Regionally, OHIP+ again made its mark in Ontario, while Atlantic Canada posted the biggest increase in average eligible costs despite leading the country in generic fill rates.
Learn more about these and other major trends in private drug-plan costs and utilization by tuning into the 2020 edition of Retrospective: Data Trends and National Benchmarks, presented by Shawn O’Brien, Principal, Business Intelligence at TELUS Health. Drawing from 2019 claims data for more than 13 million insured Canadians, O’Brien also provides updates on plan sponsors’ adoption rates of plan design tools, such as generic substitution, coinsurance and managed formularies.
